findmyKOL

Michael Donahoe, MD

Basic profile

Pulmonary Disease

ORCIDNone on fileNPI
RegionPittsburgh, PA · NortheastSpecialtyPulmonary DiseaseFocusRespiratory
Last active 2012findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationNot yet indexedOnline presenceNot yet checkedPaymentsNone reportedNIH funding2007–2012Why? →

Michael Donahoe is a Respiratory physician. ClinicalTrials.gov lists 3 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)

Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials
1NIH grants · 2007–2012

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

3601 5th Ave Fl 4
Pittsburgh, PA 152133403

Telephone

412-648-6161

Provider last certified this registry record 28 Jul 2021.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Respiratory

    67.1%
    Corticosteroid37.2%
    Trelegy Ellipta48%Budesonide-Formoterol Fumarate16%Breo Ellipta7%Symbicort6%Breyna6%Dulera6%Arnuity Ellipta3%Fluticasone Propionate3%Fluticasone Propionate Hfa3%Breztri Aerosphere2%
    Part D<11 patients
    beta2-Adrenergic Agonist22.9%
    Albuterol Sulfate Hfa85%Ventolin Hfa15%
    Part D102 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    17.8%
    Corticosteroid13.7%
    Prednisone100%
    Part D80 patients
    Proton pump inhibitor2.4%
    Omeprazole50%Pantoprazole Sodium50%
    Part D<11 patients

    + 1 more class in this area

  • Anti-infectives

    12.2%
    Macrolide Antimicrobial5.2%
    Azithromycin100%
    Part D39 patients
    Penicillins with extended spectrum3.5%
    Amoxicillin-Clavulanate Potass100%
    Part D23 patients

    + 3 more classes in this area

Where care is delivered (Part B)53% facility · 47% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20072012 per NIH RePORTER. The latest:

2 more award records behind the reveal.Reveal →

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”